PE20130379A1 - Metodos para el tratamiento de las ulceras del pie diabetico - Google Patents
Metodos para el tratamiento de las ulceras del pie diabeticoInfo
- Publication number
- PE20130379A1 PE20130379A1 PE2012001812A PE2012001812A PE20130379A1 PE 20130379 A1 PE20130379 A1 PE 20130379A1 PE 2012001812 A PE2012001812 A PE 2012001812A PE 2012001812 A PE2012001812 A PE 2012001812A PE 20130379 A1 PE20130379 A1 PE 20130379A1
- Authority
- PE
- Peru
- Prior art keywords
- weight
- treatment
- diabetic foot
- foot ulcers
- methods
- Prior art date
Links
- 208000008960 Diabetic foot Diseases 0.000 title abstract 2
- 208000025865 Ulcer Diseases 0.000 title abstract 2
- 231100000397 ulcer Toxicity 0.000 title abstract 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 abstract 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 abstract 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 abstract 2
- RUBMHAHMIJSMHA-LBWFYSSPSA-N aclerastide Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)CCCC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 RUBMHAHMIJSMHA-LBWFYSSPSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000017 hydrogel Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/085—Angiotensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA FORMULACION FARMACEUTICA QUE COMPRENDE (a) 0.5% A APROXIMADAMENTE 4% DE HIDROXIETILCELULOSA (HEC) SOBRE UNA BASE DE PESO (MG)/VOLUMEN (ML), O SOBRE UNA BASE DE PESO/ PESO (MG); (b) UN PEPTIDO DE POR LO MENOS 5 AMINOACIDOS CONTIGUOS TAL COMO ASP-ARG-NLE-TYR-ILE-HIS-PRO (SEQ ID NO:1),CON UNA CONCENTRACION DE 0.03% A APROXIMADAMENTE 1% SOBRE UNA BASE DE PESO (MG)/VOLUMEN (ML) O SOBRE UNA BASE DE PESO/PESO (MG). DICHA FORMULACION ES UN HIDROGEL, UTIL EN EL TRATAMIENTO DE ULCERAS DE PIE DIABETICO.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161438780P | 2011-02-02 | 2011-02-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20130379A1 true PE20130379A1 (es) | 2013-04-13 |
Family
ID=45571822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012001812A PE20130379A1 (es) | 2011-02-02 | 2012-02-01 | Metodos para el tratamiento de las ulceras del pie diabetico |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US8207233B1 (es) |
| EP (1) | EP2536422B8 (es) |
| JP (2) | JP5469777B2 (es) |
| KR (1) | KR101514414B1 (es) |
| CN (1) | CN102858360B (es) |
| AU (1) | AU2012212220B2 (es) |
| BR (1) | BR112013019513A2 (es) |
| CA (1) | CA2793515C (es) |
| CL (1) | CL2012002560A1 (es) |
| CO (1) | CO6592101A2 (es) |
| DK (1) | DK2536422T3 (es) |
| EA (1) | EA026440B1 (es) |
| ES (1) | ES2479765T3 (es) |
| MX (1) | MX2012010783A (es) |
| PE (1) | PE20130379A1 (es) |
| PL (1) | PL2536422T3 (es) |
| PT (1) | PT2536422E (es) |
| SG (1) | SG183960A1 (es) |
| WO (1) | WO2012106427A2 (es) |
| ZA (1) | ZA201207340B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012212220B2 (en) * | 2011-02-02 | 2013-04-04 | University Of Southern California | Methods for treating diabetic foot ulcers |
| WO2013172956A1 (en) | 2012-05-14 | 2013-11-21 | University Of Southern California | Methods for limiting development of a skin wound |
| EP2895154A4 (en) * | 2012-09-17 | 2016-04-20 | Tarix Pharmaceuticals Ltd | ORAL FORMULATIONS OF ANGIOTENSIN |
| US9289500B2 (en) * | 2013-02-22 | 2016-03-22 | The Regents Of The University Of California | Saccharide-peptide hydrogels |
| EP3935944A1 (en) | 2013-03-15 | 2022-01-12 | University Of Southern California, USC Stevens | Compounds for the treatment of musculoskeletal diseases |
| WO2014151338A1 (en) | 2013-03-15 | 2014-09-25 | University Of Southern California | Methods for treating multiple sclerosis |
| US9981011B2 (en) * | 2014-03-10 | 2018-05-29 | Rush University Medical Center | Methods of promotion of healing of diabetic wounds |
| WO2016108130A1 (en) * | 2014-12-30 | 2016-07-07 | Sun Pharmaceutical Industries Limited | Topical pharmaceutical compositions comprising nebivolol for the treatment of diabetic wounds |
| WO2017100276A1 (en) * | 2015-12-08 | 2017-06-15 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treatment, amelioration, and prevention of diabetes-related skin ulcers |
| US20240092886A1 (en) * | 2019-10-09 | 2024-03-21 | Rush University Medical Center | Modulating interleukin-10 signaling to boost healing in diabetic wounds |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5015629A (en) | 1989-06-26 | 1991-05-14 | University Of Southern California | Tissue repair |
| AU3062392A (en) * | 1991-11-04 | 1993-06-07 | Novo Nordisk A/S | Pdgf gel formulation |
| AU706333B2 (en) | 1993-09-24 | 1999-06-17 | University Of Southern California | Use of angiotensin III and analogs thereof in tissue repair |
| AU697504B2 (en) | 1993-09-24 | 1998-10-08 | University Of Southern California | Use of angiotensin II analogs in tissue repair |
| US5955430A (en) | 1993-09-24 | 1999-09-21 | University Of Southern California | Use of angiotensin II fragments and analogs thereof in tissue repair |
| US5834432A (en) | 1995-06-06 | 1998-11-10 | The University Of Southern California | Use of angiotensin II Type 2 receptor agonists in tissue repair |
| US6110895A (en) | 1996-12-16 | 2000-08-29 | University Of Southern California | Method of promoting healing in skin grafts |
| US6335195B1 (en) | 1997-01-28 | 2002-01-01 | Maret Corporation | Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation |
| WO1998033813A2 (en) | 1997-02-04 | 1998-08-06 | University Of Southern California | Method for accelerating healing of thermal injuries |
| US6248587B1 (en) | 1997-11-26 | 2001-06-19 | University Of Southern Cailfornia | Method for promoting mesenchymal stem and lineage-specific cell proliferation |
| AU755225B2 (en) | 1997-12-12 | 2002-12-05 | University Of Southern California | Wound healing compositions |
| JP2002502858A (ja) | 1998-02-09 | 2002-01-29 | ユニヴァースティ オブ サザーン カリフォルニア | ケラチノサイト増殖促進法 |
| US6455500B1 (en) | 1998-03-10 | 2002-09-24 | University Of Southern California | Radiation therapy methods |
| US7173011B2 (en) | 2000-11-20 | 2007-02-06 | University Of Southern California | Radiation therapy methods |
| US6498138B1 (en) | 1998-03-11 | 2002-12-24 | University Of Southern California | Method of promoting production of living tissue equivalents |
| US6762167B1 (en) | 1998-05-11 | 2004-07-13 | University Of Southern California | Methods for treating a patient undergoing chemotherapy |
| JP2003521441A (ja) | 1998-05-11 | 2003-07-15 | ユニヴァースティ オブ サザーン カリフォルニア | 化学療法後の白血球生残率を増加させる方法 |
| US6916783B2 (en) | 1998-07-13 | 2005-07-12 | University Of Southern California | Methods for accelerating bone and cartilage growth and repair |
| US6258778B1 (en) | 1998-07-13 | 2001-07-10 | University Of Southern California | Methods for accelerating bone and cartilage growth and repair |
| JP2002522505A (ja) | 1998-08-13 | 2002-07-23 | ユニヴァースティ オブ サザーン カリフォルニア | 虚血組織への血流を増加させる方法 |
| US6730775B1 (en) | 1999-03-23 | 2004-05-04 | University Of Southern California | Methods for limiting scar and adhesion formation |
| US7338938B2 (en) | 1999-05-10 | 2008-03-04 | University Of Southern California | Methods for treating a patient undergoing chemotherapy |
| AU1792901A (en) | 1999-12-16 | 2001-06-25 | University Of Southern California | Methods for treating and preventing diabetic complications |
| US6821953B1 (en) | 1999-12-16 | 2004-11-23 | University Of Southern California | Methods for treating and preventing damage to mucosal tissue |
| AU2001218024A1 (en) * | 2000-06-19 | 2002-01-02 | University Of Southern California | Methods for treating and preventing alopecia |
| US20060058238A1 (en) * | 2004-09-15 | 2006-03-16 | Lee Laurent-Applegate | Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same |
| WO2009075881A2 (en) * | 2007-12-11 | 2009-06-18 | Coda Therapeutics, Inc. | Impaired wound healing compositions and treatments |
| US20090227507A1 (en) | 2008-03-10 | 2009-09-10 | University Of Southern California | Angiotensin (1-7) Dosage Forms and Uses Thereof |
| EA022388B1 (ru) * | 2010-03-26 | 2015-12-30 | Университи Оф Сатерн Калифорния | Способы лечения комбинированных лучевых и тепловых поражений |
| WO2012021578A1 (en) | 2010-08-10 | 2012-02-16 | University Of Southern California | Use of angiotensin- ii (1-7) in cell trans planation and as an agent for preventing/treating norovirus infection |
| AU2012212220B2 (en) * | 2011-02-02 | 2013-04-04 | University Of Southern California | Methods for treating diabetic foot ulcers |
-
2012
- 2012-02-01 AU AU2012212220A patent/AU2012212220B2/en not_active Ceased
- 2012-02-01 WO PCT/US2012/023484 patent/WO2012106427A2/en not_active Ceased
- 2012-02-01 PL PL12703408T patent/PL2536422T3/pl unknown
- 2012-02-01 PE PE2012001812A patent/PE20130379A1/es not_active Application Discontinuation
- 2012-02-01 ES ES12703408.0T patent/ES2479765T3/es active Active
- 2012-02-01 CN CN201280001085.4A patent/CN102858360B/zh not_active Expired - Fee Related
- 2012-02-01 KR KR1020127023804A patent/KR101514414B1/ko not_active Expired - Fee Related
- 2012-02-01 EA EA201201296A patent/EA026440B1/ru not_active IP Right Cessation
- 2012-02-01 BR BR112013019513A patent/BR112013019513A2/pt not_active Application Discontinuation
- 2012-02-01 EP EP12703408.0A patent/EP2536422B8/en active Active
- 2012-02-01 US US13/364,061 patent/US8207233B1/en active Active
- 2012-02-01 DK DK12703408.0T patent/DK2536422T3/da active
- 2012-02-01 JP JP2013502927A patent/JP5469777B2/ja not_active Expired - Fee Related
- 2012-02-01 CA CA2793515A patent/CA2793515C/en active Active
- 2012-02-01 MX MX2012010783A patent/MX2012010783A/es active IP Right Grant
- 2012-02-01 PT PT127034080T patent/PT2536422E/pt unknown
- 2012-02-01 SG SG2012066452A patent/SG183960A1/en unknown
- 2012-04-06 US US13/441,653 patent/US8207234B1/en active Active
- 2012-05-09 US US13/467,253 patent/US8536231B2/en not_active Expired - Fee Related
- 2012-09-10 CO CO12154938A patent/CO6592101A2/es unknown
- 2012-09-14 CL CL2012002560A patent/CL2012002560A1/es unknown
- 2012-10-01 ZA ZA2012/07340A patent/ZA201207340B/en unknown
-
2013
- 2013-12-19 JP JP2013262634A patent/JP2014080425A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2793515A1 (en) | 2012-08-09 |
| PL2536422T3 (pl) | 2014-09-30 |
| AU2012212220B2 (en) | 2013-04-04 |
| PT2536422E (pt) | 2014-07-18 |
| EP2536422A2 (en) | 2012-12-26 |
| ES2479765T3 (es) | 2014-07-24 |
| EA201201296A1 (ru) | 2013-02-28 |
| JP2013523781A (ja) | 2013-06-17 |
| US8207234B1 (en) | 2012-06-26 |
| SG183960A1 (en) | 2012-10-30 |
| ZA201207340B (en) | 2013-02-27 |
| HK1180213A1 (en) | 2013-10-18 |
| US8207233B1 (en) | 2012-06-26 |
| CN102858360A (zh) | 2013-01-02 |
| KR20120137365A (ko) | 2012-12-20 |
| BR112013019513A2 (pt) | 2019-06-11 |
| EA026440B1 (ru) | 2017-04-28 |
| CO6592101A2 (es) | 2013-01-02 |
| KR101514414B1 (ko) | 2015-05-04 |
| MX2012010783A (es) | 2012-11-23 |
| CA2793515C (en) | 2015-05-12 |
| JP2014080425A (ja) | 2014-05-08 |
| CN102858360B (zh) | 2017-07-25 |
| EP2536422B8 (en) | 2023-06-21 |
| WO2012106427A3 (en) | 2012-09-20 |
| JP5469777B2 (ja) | 2014-04-16 |
| WO2012106427A2 (en) | 2012-08-09 |
| CL2012002560A1 (es) | 2013-03-22 |
| US8536231B2 (en) | 2013-09-17 |
| DK2536422T3 (da) | 2014-07-28 |
| US20120329729A1 (en) | 2012-12-27 |
| AU2012212220A1 (en) | 2012-10-18 |
| EP2536422B1 (en) | 2014-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20130379A1 (es) | Metodos para el tratamiento de las ulceras del pie diabetico | |
| NI201200013A (es) | Composición de insulina de acción prolongada | |
| CO6382125A2 (es) | Inhibidores de proteína quinasa | |
| MX366906B (es) | Purificacion de iduronato-2-sulfatasa. | |
| CL2009001340A1 (es) | Compuesto de insulina lispro pegilada o una sal del mismo que comprende una cadena a de sec no:1, una cadena b de sec no:3 y el peg es de un peso entre 20 a 40 kda; uso de dicho compuesto para tratar hipoglicemia o diabetes; composición farmacéutica que comprende dicho compuesto; y proceso para elaborar dicho compuesto. | |
| EA201590058A1 (ru) | Аналоги глюкагона | |
| PA8811601A1 (es) | Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado | |
| AR092925A1 (es) | Derivados de exendina-4 como agonistas duales de glp1 / glucagon | |
| AR083162A1 (es) | Uso de ingredientes activos para controlar nematodos en cultivos resistentes a nematodos | |
| AR091422A1 (es) | Analogos peptidicos de la exendina 4 | |
| MX2016001971A (es) | Composiciones farmaceuticas parenterales acuosas estables de peptidos insulinotropicos. | |
| CY1119582T1 (el) | Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη | |
| BR112012016853A2 (pt) | "composições farmacêuticas para administração oral de peptídeos de insulina". | |
| EA201370178A1 (ru) | Стабильные составы для парентеральной инъекции пептидных лекарственных средств | |
| CL2014002556A1 (es) | Compuestos derivados de ácidos indaniloxidihidrobenzofuranilacéticos, agonistas del receptor gpr40; composiicon farmaceutica; y su uso en el tratamiento de enfermedades o afecciones como diabetes, resistencia a la insulina, obesidad, entre otras. | |
| DOP2011000343A (es) | Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral | |
| PE20141672A1 (es) | FORMULACION PARA ANTICUERPO ANTI-alfa4�7 | |
| NI201200017A (es) | Formulación farmacéutica | |
| UY32240A (es) | Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones. | |
| BR112012013487A2 (pt) | Composições de amantadina e métodos de uso | |
| PH12015501931B1 (en) | Treatment of diabetes mellitus by long-acting formulations of insulins | |
| NI201000173A (es) | Uso de dronedarona o una sal aceptable farmacéuticamente de ésta, para la preparación de un medicamento para regular el nivel de potasio en la sangre. | |
| AR075041A1 (es) | Composicion farmaceutica que contiene aleglitazar, proceso, uso. | |
| CL2009001006A1 (es) | Compuestos derivados del acido 4-dimetil-aminobutirico; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como hiperglucemia, diabetes e hipertension entre otras. | |
| EA201490041A1 (ru) | Пластырь, содержащий диклофенак и тиоколхикозид |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |